Akash Tewari Analyst PerformanceGlobal Head of Biopharmaceutical Research at Jefferies Financial GroupAkash Tewari is a stock analyst at Jefferies Financial Group in the medical sector, covering 19 publicly traded companies. Over the past year, Akash Tewari has issued 20 stock ratings, including buy and hold recommendations. While full access to Akash Tewari's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Akash Tewari's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings28 Last 4 YearsBuy Recommendations80.77% 21 Buy RatingsCompanies Covered19 Unique Companies Ratings Distribution26RatingsDistribution of strong buy, buy, hold, and sell ratings by Akash Tewari.RatingPercentageCount Strong Buy0.0%0 ratings Buy80.8%21 ratings Hold15.4%4 ratings Sell3.8%1 ratingsOut of 26 total stock ratings issued by Akash Tewari at Jefferies Financial Group, the majority (80.8%) have been Buy recommendations, followed by 15.4% Hold and 3.8% Sell.Best & Worst CallsBest Call000.0%BMYApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%EXELMay 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ84.2% of companies on NASDAQ16 companiesNYSE15.8% of companies on NYSE3 companiesAkash Tewari, an analyst at Jefferies Financial Group, currently covers 19 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical19 companies100.0%Akash Tewari of Jefferies Financial Group specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE14 companies73.7%MED - DRUGS3 companies15.8%LARGE CAP PHARMA2 companies10.5% Akash Tewari's Ratings History at Jefferies Financial Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSYRESpyre Therapeutics4/13/2026Boost Price Target$64.08$85.00Buy$0.0000.00% ROIBNTXBioNTech3/25/2026Reiterated Rating$86.81Buy$0.0000.00% ROILLYEli Lilly and Company3/13/2026Set Price Target$998.85$1,300.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical3/12/2026Reiterated Rating$60.12$103.00Buy$0.0000.00% ROIAMGNAmgen3/10/2026Initiated Coverage$376.97$350.00Hold$0.0000.00% ROIGILDGilead Sciences3/10/2026Initiated Coverage$146.63$180.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Initiated Coverage$460.87$580.00Buy$0.0000.00% ROIBNTXBioNTech3/10/2026Lower Price Target$84.09$138.00Buy$0.0000.00% ROIAPGEApogee Therapeutics2/2/2026Reiterated Rating$66.06$95.00Buy$0.0000.00% ROICYTKCytokinetics1/9/2026Reiterated Rating$64.41$90.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals12/10/2025Reiterated Rating$44.81$70.00Buy$0.0000.00% ROIBNTXBioNTech12/3/2025Reiterated Rating$96.78$151.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals11/3/2025Boost Price Target$14.03$35.00Buy$0.0000.00% ROIALKSAlkermes10/28/2025Set Price Target$30.97$56.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical10/28/2025Reiterated Rating$52.67Outperform$0.0000.00% ROIENTAEnanta Pharmaceuticals10/1/2025Upgrade$10.93$20.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/2/2025Boost Price Target$57.43$96.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals8/27/2025Boost Price Target$587.65$831.00Buy$0.0000.00% ROICBIOCrescent Biopharma8/25/2025Initiated Coverage$15.06$26.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical7/15/2025Set Price Target$58.23$95.00Outperform$0.0000.00% ROIARVNArvinas5/2/2025Reiterated Rating$7.23$10.00Hold$00.0000.00% ROIBMYBristol Myers Squibb4/23/2025Lower Price Target$49.82$68.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenRoyal Bank Of CanadaStifel NicolausBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper Sandler Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
